immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients

TUEBINGEN, Germany, April 11, 2011 - immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company
developing advanced therapeutic vaccines that are active against cancer,
today announced that Pfizer has agreed to support its pivotal Phase III trial
(IMPRINT = IMA901 Multi-Peptide vaccine Randomized INTernational study) with
IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

The pivotal Phase III study will evaluate as the primary
endpoint the overall survival of advanced renal cell carcinoma patients
treated with IMA901 in combination with Pfizer's Sutent(R) (sunitinib malate)
versus Sutent(R) alone. The study is expected to enroll approximately 330
patients across Europe and in the US.

Pfizer will support the trial by supplying Sutent(R) for all
the patients enrolled in the pivotal study. The first patients are expected
to start treatment in April 2011.

Paul Higham, CEO of immatics, said: "We are extremely pleased
that Pfizer has committed to supporting our pivotal Phase III trial with
IMA901 with the supply of Sutent. Their decision reflects the growing
interest in IMA901 and its potential to be an important breakthrough in the
treatment of renal cell carcinoma patients."

IMA901 has generated encouraging overall survival data, which
compare favorably with historical comparisons of currently available
treatments, in a Phase II trial in advanced renal cell carcinoma patients.
Importantly, the Phase II study also showed an association between survival
and the patient's immune response to IMA901, as well as confirming the
favorable safety profile observed in an earlier Phase I study.

"Pfizer is pleased to provide Sutent to support immatic's
clinical development program in advanced renal cell carcinoma patients," said
Craig Eagle, Vice President of Strategic Alliances and Partnerships for
Pfizer Oncology. "This collaboration underscores Pfizer's ongoing commitment
to the discovery, investigation and development of innovative treatment
options to improve the outlook for cancer patients worldwide."

For more information on SUTENT and Pfizer please visit
www.pfizer.com.

About IMA901

IMA901 is a therapeutic cancer vaccine comprising 10
tumor-associated peptides (TUMAPs) that are frequently found to be
over-expressed in the majority of patients suffering from renal cell
carcinoma. As with all immatics' vaccines, IMA901 has been designed to elicit
a strong, clinically relevant immune response to a specific tumor type. The
TUMAPs were selected from over 2,000 peptides identified via immatics' unique
XPRESIDENT(TM) platform. TUMAPs included in IMA901 are from targets with
vital functions for the tumor, for example invasion, neo-angiogenesis.

About SUTENT((R)) (sunitinib malate)

SUTENT is an oral multi-kinase inhibitor approved for the
treatment of advanced/metastatic renal cell carcinoma (RCC), unresectable
and/or metastatic malignant gastrointestinal stromal tumor (GIST) after
failure of imatinib mesilate treatment due to resistance or intolerance.

In Europe, SUTENT is also indicated for the treatment of
unresectable or metastatic, well-differentiated pancreatic neuroendocrine
tumours with disease progression in adults. Experience with SUTENT as
first-line treatment is limited.

SUTENT works by blocking multiple molecular targets implicated
in the growth, proliferation and spread of cancer. Two important SUTENT
targets, vascular endothelial growth factor receptor (VEGFR) and
platelet-derived growth factor receptor (PDGFR), are expressed by many types
of solid tumors and are thought to play a crucial role in angiogenesis, the
process by which tumors acquire blood vessels, oxygen and nutrients needed
for growth. SUTENT also inhibits other targets important to tumor growth,
including KIT, FLT3 and RET.

Important SUTENT((R)) (sunitinib malate) Safety Information

Hepatotoxicity has been observed in clinical trials and
post-marketing experience. Cases of hepatic failure, some with a fatal
outcome, were observed in <1% of solid tumor patients treated with SUTENT. It
is recommended to monitor liver function tests before initiation of
treatment, during each cycle of treatment, and as clinically indicated. If
signs or symptoms of hepatic failure are present, sunitinib should be
discontinued and appropriate supportive care should be provided.

Women of child bearing age who are (or become) pregnant during
therapy should be informed of the potential for fetal harm while on SUTENT.

Decreases in left ventricular ejection fraction (LVEF) to
below the lower limit of normal (LLN) have been observed. Patients with
concomitant cardiac conditions should be carefully monitored for clinical
signs and symptoms of congestive heart failure. Patients should be monitored
for hypertension and treated as needed with standard antihypertensive
therapy. Complete blood counts (CBCs) with platelet count and serum
chemistries should be performed at the beginning of each treatment cycle for
patients receiving treatment with SUTENT.

The most common adverse reactions in GIST, RCC and pancreatic
NET clinical trials were diarrhea, fatigue, asthenia, nausea,
mucositis/stomatitis, anorexia, vomiting, neutropenia, hypertension,
dyspepsia, abdominal pain, constipation, rash, hand-foot syndrome, skin
discoloration, hair color changes, altered taste and bleeding. For more
information on SUTENT and Pfizer Oncology, including full prescribing
information for SUTENT (sunitinib malate), please visit www.pfizer.com.

About immatics

immatics biotechnologies is a clinical-stage biopharmaceutical
company developing rationally designed therapeutic vaccines that are active
against cancer. immatics' lead product, IMA901, has completed a successful
phase II trial in renal cell carcinoma. immatics' pipeline also includes
IMA910, in phase II for colorectal cancer, and IMA950 which is in phase I for
glioma.

immatics' XPRESIDENT(TM) technology platform rapidly generates
defined therapeutic cancer vaccines, based on multiple tumor-associated
peptides (TUMAPs), that have the ability to specifically stimulate the immune
system against cancer cells. These vaccines - comprising multiple peptides
confirmed to be naturally presented by real tumor tissue - offer the prospect
of greater effectiveness than existing cancer vaccine approaches. immatics'
products are 'drug like' with stable, off-the-shelf formulations and robust
easily scalable manufacturing.

immatics is based in Tuebingen and Munich, Germany.

    For additional information on immatics please visit
    www.immatics.com or contact:

    Paul Higham, CEO
    Katrin Eckert, Assistant to the Management
    immatics biotechnologies GmbH
    Phone: +49-7071-5397-110
    E-mail: media@immatics.com

    David Dible / Chris Gardner / Sita Shah
    Citigate Dewe Rogerson
    Phone: +44-207-638-9571
    E-mail: david.dible@citigatedr.co.uk

For additional information on immatics please visit www.immatics.com or contact: Paul Higham, CEO, Katrin Eckert, Assistant to the Management, immatics biotechnologies GmbH, Phone: +49-7071-5397-110, E-mail: media at immatics.com . David Dible / Chris Gardner / Sita Shah, Citigate Dewe Rogerson, Phone: +44-207-638-9571, E-mail: david.dible at citigatedr.co.uk .